OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Entry into a Material Definitive Agreement
Item1.01
| Entry into a Material Definitive Agreement. |
| Item2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. |
On March17, 2017, a wholly-owned subsidiary of OPKO Health, Inc.
(the Company), Bio-Reference Laboratories, Inc., a New
Jersey corporation (BRLI), and certain of its subsidiaries
entered into Amendment No.3 to Credit Agreement (the
Amendment), which amends that certain Credit Agreement (as
amended, the Credit Agreement), dated as of November5,
2015, by and among BRLI, certain of its subsidiaries from time to
time party thereto, the lenders from time to time party thereto
and JPMorgan Chase Bank, N.A., as administrative agent for the
lenders, to permit BRLI and its subsidiaries to dividend cash to
the Company in the form of an intercompany loan, in an aggregate
amount not to exceed $55,000,000. The other terms of the Credit
Agreement remain unchanged.
The foregoing descriptions of the Credit Agreement and the
Amendment are only summaries and are qualified in their entirety
by references to the terms of the Credit Agreement and the
Amendment, copies of which are attached to this Current Report on
Form 8-K as Exhibits 10.1 and 10.2, respectively, and
incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
(d)Exhibits
| Exhibit | Description | |
| 10.1 |
Credit Agreement, dated as of November5, 2015, among Bio-Reference Laboratories, Inc. and certain of its subsidiaries and JPMorgan Chase Bank, N.A. (previously filed as exhibit 10.22 to the Companys Annual Report on Form 10-K filed on February29, 2016, and incorporated by reference herein). |
|
| 10.2 |
Amendment No.3 to Credit Agreement, dated as of March17, 2017, among Bio-Reference Laboratories, Inc. and certain of its subsidiaries and JPMorgan Chase Bank, N.A. |
2
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. OPKO Health, Inc. (NASDAQ:OPK) Recent Trading Information
OPKO Health, Inc. (NASDAQ:OPK) closed its last trading session down -0.21 at 7.65 with 3,081,437 shares trading hands.
